Q3 EPS Forecast for Denali Therapeutics Increased by Analyst

Denali Therapeutics Inc. (NASDAQ:DNLI) – Stock analysts at HC Wainwright boosted their Q3 2026 earnings estimates for Denali Therapeutics in a research report issued to clients and investors on Friday, August 7th. HC Wainwright analyst A. Fein now forecasts that the company will post earnings of ($0.67) per share for the quarter, up from their previous estimate of ($0.68). The consensus estimate for Denali Therapeutics’ current full-year earnings is ($2.73) per share. HC Wainwright also issued estimates for Denali Therapeutics’ FY2026 earnings at ($2.70) EPS, FY2027 earnings at ($2.54) EPS, FY2028 earnings at ($2.46) EPS, FY2029 earnings at ($1.35) EPS and FY2030 earnings at $0.01 EPS.

Denali Therapeutics (NASDAQ:DNLI) last posted its quarterly earnings results on Thursday, August 6th. The company reported ($0.68) EPS for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.17). The firm had revenue of $3.60 million for the quarter, compared to analysts’ expectations of $2.15 million. During the same quarter last year, the firm posted ($0.72) EPS.

DNLI has been the topic of several other reports. Robert W. Baird set a $34.00 target price on Denali Therapeutics in a research note on Friday. Leerink Partners decreased their price target on Denali Therapeutics from $40.00 to $35.00 and set an “outperform” rating for the company in a research note on Wednesday, April 22nd. Wedbush reaffirmed an “outperform” rating and set a $26.00 price target on shares of Denali Therapeutics in a report on Monday, July 13th. Deutsche Bank Aktiengesellschaft increased their price objective on Denali Therapeutics from $31.00 to $35.00 and gave the company a “buy” rating in a research report on Thursday, July 16th. Finally, Stifel Nicolaus set a $41.00 price objective on Denali Therapeutics in a report on Monday, June 22nd. Thirteen equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, Denali Therapeutics presently has a consensus rating of “Moderate Buy” and an average price target of $35.92.

Denali Therapeutics Price Performance

Shares of NASDAQ DNLI opened at $25.00 on Tuesday. Denali Therapeutics has a twelve month low of $12.58 and a twelve month high of $27.30. The firm has a market cap of $3.97 billion, a P/E ratio of -8.80 and a beta of 1.01. The company has a 50 day moving average of $23.63 and a 200 day moving average of $21.35. The company has a quick ratio of 8.32, a current ratio of 8.37 and a debt-to-equity ratio of 0.01.

Institutional Trading of Denali Therapeutics

A number of hedge funds have recently bought and sold shares of the company. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its position in Denali Therapeutics by 4.0% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 88,507 shares of the company’s stock valued at $1,210,000 after acquiring an additional 3,432 shares during the last quarter. Goldman Sachs Group Inc. boosted its position in Denali Therapeutics by 58.1% in the first quarter. Goldman Sachs Group Inc. now owns 1,672,078 shares of the company’s stock worth $22,732,000 after purchasing an additional 614,555 shares during the last quarter. Empowered Funds LLC boosted its position in Denali Therapeutics by 11.0% in the first quarter. Empowered Funds LLC now owns 20,639 shares of the company’s stock worth $281,000 after purchasing an additional 2,052 shares during the last quarter. Woodline Partners LP grew its stake in shares of Denali Therapeutics by 13.5% during the 1st quarter. Woodline Partners LP now owns 113,517 shares of the company’s stock valued at $1,543,000 after purchasing an additional 13,517 shares during the period. Finally, JPMorgan Chase & Co. grew its stake in shares of Denali Therapeutics by 1.7% during the 2nd quarter. JPMorgan Chase & Co. now owns 191,613 shares of the company’s stock valued at $2,681,000 after purchasing an additional 3,210 shares during the period. Hedge funds and other institutional investors own 92.92% of the company’s stock.

Denali Therapeutics Company Profile

Denali Therapeutics is a clinical‐stage biopharmaceutical company focused on developing therapies for neurodegenerative diseases. The company’s research leverages a proprietary Blood–Brain Barrier Transport Vehicle (TV) platform designed to enable large molecules, including antibodies and enzymes, to penetrate the central nervous system. Denali’s approach includes small molecules, monoclonal antibodies and gene therapy candidates aimed at key drivers of disorders such as Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis (ALS) and frontotemporal dementia.

Among Denali’s lead programs is an orally delivered leucine‐rich repeat kinase 2 (LRRK2) inhibitor for Parkinson’s disease, and an anti‐TREM2 antibody designed to modulate microglial activity in Alzheimer’s patients.